JP5431954B2 - ＩｎＶｉｖｏ造影剤 - Google Patents

ＩｎＶｉｖｏ造影剤 Download PDF

Info

Publication number
JP5431954B2
JP5431954B2 JP2009542206A JP2009542206A JP5431954B2 JP 5431954 B2 JP5431954 B2 JP 5431954B2 JP 2009542206 A JP2009542206 A JP 2009542206A JP 2009542206 A JP2009542206 A JP 2009542206A JP 5431954 B2 JP5431954 B2 JP 5431954B2
Authority
JP
Japan
Prior art keywords
compound
formula
contrast agent
contrast
ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009542206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513441A (ja
JP2010513441A5 (enExample
Inventor
ストーリー，トニー
デイビス，ジュリー
アースタッド，エリック
ギルバード，ベネディクト
ガエタ，アレッサンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hammersmith Imanet Ltd
Original Assignee
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hammersmith Imanet Ltd filed Critical Hammersmith Imanet Ltd
Publication of JP2010513441A publication Critical patent/JP2010513441A/ja
Publication of JP2010513441A5 publication Critical patent/JP2010513441A5/ja
Application granted granted Critical
Publication of JP5431954B2 publication Critical patent/JP5431954B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009542206A 2006-12-21 2007-12-19 ＩｎＶｉｖｏ造影剤 Expired - Fee Related JP5431954B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625523.6 2006-12-21
GBGB0625523.6A GB0625523D0 (en) 2006-12-21 2006-12-21 In vivo imaging agents
PCT/GB2007/004880 WO2008075040A2 (en) 2006-12-21 2007-12-19 In vivo imaging agents

Publications (3)

Publication Number Publication Date
JP2010513441A JP2010513441A (ja) 2010-04-30
JP2010513441A5 JP2010513441A5 (enExample) 2011-01-13
JP5431954B2 true JP5431954B2 (ja) 2014-03-05

Family

ID=37734613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542206A Expired - Fee Related JP5431954B2 (ja) 2006-12-21 2007-12-19 ＩｎＶｉｖｏ造影剤

Country Status (8)

Country Link
US (3) US20110129419A1 (enExample)
EP (1) EP2125038B1 (enExample)
JP (1) JP5431954B2 (enExample)
CN (1) CN101678129B (enExample)
AT (1) ATE555814T1 (enExample)
ES (1) ES2384002T3 (enExample)
GB (1) GB0625523D0 (enExample)
WO (1) WO2008075040A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
JP5656408B2 (ja) 2006-12-26 2015-01-21 ランセウス メディカル イメージング， インコーポレイテッド 心臓の神経支配を画像化するためのリガンド
EP2036578A1 (en) * 2007-09-13 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols
CN102858752B (zh) 2010-02-08 2018-10-16 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
RU2710736C2 (ru) 2010-05-11 2020-01-10 Лантеус Медикал Имэджинг, Инк. Композиции, способы и системы для синтеза и применение визуализирующих средств
CN101921224B (zh) * 2010-05-21 2012-01-18 中国人民解放军军事医学科学院生物工程研究所 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用
US9649394B2 (en) * 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
KR102527562B1 (ko) * 2011-09-09 2023-05-03 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP3493855A4 (en) 2016-08-02 2020-04-01 ISI Life Sciences, Inc. METHOD FOR DETECTION OF CANCER CELLS.
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1310621A (zh) * 1998-07-28 2001-08-29 史密丝克莱恩比彻姆公司 取代的n－酰苯胺化合物和方法
TR200103214T2 (tr) * 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
PE20010628A1 (es) * 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
NZ519183A (en) * 1999-12-03 2005-02-25 Ono Pharmaceutical Co Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SK1142003A3 (en) * 2000-07-31 2003-06-03 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11CBY receptor
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
GB0115929D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase electrophilic fluorination
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
SE0103819D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
GB0127547D0 (en) * 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
WO2006102395A2 (en) 2005-03-22 2006-09-28 Medstar Health Inc Delivery systems and methods for diagnosing and treating cardiovascular diseases

Also Published As

Publication number Publication date
JP2010513441A (ja) 2010-04-30
US20130129625A1 (en) 2013-05-23
GB0625523D0 (en) 2007-01-31
CN101678129B (zh) 2013-01-16
ATE555814T1 (de) 2012-05-15
CN101678129A (zh) 2010-03-24
US20110129419A1 (en) 2011-06-02
WO2008075040A3 (en) 2009-11-05
EP2125038A2 (en) 2009-12-02
US20130129626A1 (en) 2013-05-23
ES2384002T3 (es) 2012-06-28
EP2125038B1 (en) 2012-05-02
WO2008075040A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
JP5431954B2 (ja) ＩｎＶｉｖｏ造影剤
CN102712603B (zh) 放射性碘标记方法
KR20190119673A (ko) 시트레이트 완충제 내 18ｆ―플루시클로빈 조성물
WO2014052454A1 (en) Imaging agents
US20120034165A1 (en) Imaging the central nervous system with purinergic p2x7 receptor binding agents
CN111662270A (zh) 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
JP5085824B2 (ja) 低酸素の検出のために有用な化合物の製造
CN105324367B (zh) 金属络合物及其氟化
US20120003154A1 (en) Aryloxyanilide derivatives
JP2013515036A (ja) 放射性ヨウ素化トロパン誘導体
WO2008003954A1 (en) Dye imaging agents
EP2247316B1 (en) Imaging the central nervous system
US9186424B2 (en) Aryloxyanilide imaging agents
US20130272961A1 (en) Radioiodinated guanidines
JP2014521628A (ja) 新規化合物
US8153679B2 (en) Radiolabelled inhibitors of the glycine 1 transporter
US12522579B2 (en) Monoamine oxidase B imaging probe
JP4941926B2 (ja) 診断用薬剤
US20210230139A1 (en) Monoamine oxidase b imaging probe
CN105339013A (zh) 金属络合物及其氟化

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131205

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees